Eprodisate Sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326900

CAS#: 36589-58-9 (Sodium)

Description: Eprodisate, also known as 3-PDS; NC-503; 3PDS, is an orally available disodium salt form of eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis. Upon administration, eprodisate competitively binds to the glycosaminoglycan binding sites on serum amyloid A (SAA), which inhibits the formation of the glycosaminoglycan-amyloid fibril aggregate. This prevents the formation of amyloid deposits in certain organs, especially the kidneys, in AA amyloidosis.

Price and Availability

Size Price Shipping out time Quantity
500mg USD 90 2 weeks
1g USD 150 2 weeks
2g USD 250 2 weeks
5g USD 450 2 weeks
10g USD 650 2 weeks
20g USD 1050 2 weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

Eprodisate Sodium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326900
Name: Eprodisate Sodium
CAS#: 36589-58-9 (Sodium)
Chemical Formula: C3H6Na2O6S2
Exact Mass:
Molecular Weight: 248.1745
Elemental Analysis: C, 14.52; H, 2.44; Na, 18.53; O, 38.68; S, 25.84

Synonym: 3-PDS; NC-503; 3PDS; Eprodisate Sodium; Kiacta.

IUPAC/Chemical Name: 1,3-Propanedisulfonic acid, disodium salt


InChi Code: InChI=1S/C3H8O6S2.2Na/c4-10(5,6)2-1-3-11(7,8)9;;/h1-3H2,(H,4,5,6)(H,7,8,9);;/q;2*+1/p-2

SMILES Code: O=S(CCCS(=O)([O-])=O)([O-])=O.[Na+].[Na+]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Related CAS#
36589-58-9(Eprodisate Sodium)


1: Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014 Oct 29;6:369-77. doi: 10.2147/CLEP.S39981. eCollection 2014. Review. PubMed PMID: 25378951; PubMed Central PMCID: PMC4218891.

2: Wang P, Ding K. Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease. Protein Pept Lett. 2014;21(10):1048-56. Review. PubMed PMID: 24975673.

3: Rumjon A, Coats T, Javaid MM. Review of eprodisate for the treatment of renal disease in AA amyloidosis. Int J Nephrol Renovasc Dis. 2012;5:37-43. doi: 10.2147/IJNRD.S19165. Epub 2012 Feb 24. PubMed PMID: 22427728; PubMed Central PMCID: PMC3304340.

4: Martínez-Valle F, Gironella-Mesa M, Solans-Laqué R. [New trends in the treatment of amyloidosis]. Med Clin (Barc). 2012 May 26;138(15):667-72. doi: 10.1016/j.medcli.2011.09.032. Epub 2011 Dec 22. Review. Spanish. PubMed PMID: 22197598.

5: Herrera GA, Teng J, Turbat-Herrera EA. Renal amyloidosis: current views on pathogenesis and impact on diagnosis. Contrib Nephrol. 2011;169:232-46. doi: 10.1159/000314795. Epub 2011 Jan 20. PubMed PMID: 21252523.

6: Zdrojewski Z. [Amyloidosis in rheumatic diseases]. Ann Acad Med Stetin. 2010;56 Suppl 1:7-15. Review. Polish. PubMed PMID: 21365934.

7: Blank N, Lorenz HM. [Diagnostics and therapy of AA amyloidosis]. Pathologe. 2009 May;30(3):219-25. doi: 10.1007/s00292-009-1140-5. Review. German. PubMed PMID: 19333604.

8: Manenti L, Tansinda P, Vaglio A. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert Opin Pharmacother. 2008 Aug;9(12):2175-80. doi: 10.1517/14656566.9.12.2175 . Review. PubMed PMID: 18671471.

9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51. PubMed PMID: 18597009.

10: Pani A. [A new treatment of renal disease in AA amyloidosis...and not only that?]. G Ital Nefrol. 2008 Jan-Feb;25(1):12. Italian. PubMed PMID: 18264913.

11: Rule AD, Leung N. Eprodisate slows the progression of renal disease in patients with AA amyloidosis. Nat Clin Pract Nephrol. 2007 Nov;3(11):592-3. Epub 2007 Sep 18. PubMed PMID: 17876351.

12: Manenti L, Tansinda P, Vaglio A. Eprodisate in AA amyloidosis. N Engl J Med. 2007 Sep 13;357(11):1153; author reply 1153-4. PubMed PMID: 17855678.

13: Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Filipowicz-Sosnowska A, Gül A, Merlini G, Wiland P, Ozdogan H, Gorevic PD, Maïz HB, Benson MD, Direskeneli H, Kaarela K, Garceau D, Hauck W, Van Rijswijk MH. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid. 2007 Jun;14(2):133-40. Erratum in: Amyloid. 2007 Dec;14(4):325. PubMed PMID: 17577686.

14: Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2413-5. PubMed PMID: 17554124.

15: Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. PubMed PMID: 17554116.

16: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45. PubMed PMID: 17520107.

17: Grateau G, Valleix S, Callard P. [Multisystemic amyloidosis in 2007]. Rev Med Interne. 2007 May;28(5):281-3. Epub 2007 Jan 26. Review. French. PubMed PMID: 17291633.